NEW YORK – UK transplant diagnostic company Verici DX said on Wednesday that it has inked an exclusive global licensing and commercialization agreement with Thermo Fisher Scientific to further develop a pre-transplant prognostic assay for the risk of early kidney rejection.
Financial terms of the deal were not disclosed.
Under the agreement, Verici DX grants Thermo Fisher the exclusive license to develop and offer an assay for pre-transplant risk assessment as a laboratory-developed test in its CLIA laboratory in the US, as well as worldwide rights to commercialize the test in other parts of the globe.
Verici DX said the aim of the partnership is to develop a test that can risk-stratify patients based on their likely immune response to a transplanted kidney, enabling clinicians to make more informed decisions about post-transplant and immunosuppressive management.
The company's technology leverages artificial intelligence to analyze transcriptomes and provide RNA signatures that may offer information about immune response and other biological pathways important to transplant prognosis of risk of injury, rejection, and graft failure surrounding kidney transplantation, it said.